AI-Driven Monoclonal Antibody Optimization Platform
PREDICT-mAb represents a paradigm shift in antibody engineering, leveraging cutting-edge artificial intelligence to navigate the astronomical sequence space of therapeutic antibodies. Traditional antibody development is plagued by high failure rates and prohibitive costs—our platform transforms this landscape by computationally predicting optimal candidates before lab synthesis.
By integrating deep learning architectures with structural biology insights and immunological principles, PREDICT-mAb predicts critical therapeutic properties: binding affinity, developability, immunogenicity risk, and manufacturing stability. This comprehensive optimization dramatically accelerates discovery timelines while reducing the experimental burden on researchers.
Advanced AI-Powered Features
Screen millions of antibody variants in silico within hours, identifying optimal candidates 100x faster than traditional methods while maintaining experimental accuracy.
Predict manufacturing challenges early: aggregation propensity, chemical stability, viscosity, and expression yield—ensuring candidates are not just effective but manufacturable at scale.
Identify and eliminate T-cell epitopes and immunogenic liabilities through AI-driven sequence analysis, dramatically reducing the risk of adverse immune responses in patients.
Fine-tune binding kinetics with sub-nanomolar precision, balancing target affinity against off-target effects to maximize therapeutic efficacy while minimizing side effects.
Simultaneously optimize across multiple therapeutic criteria—binding, stability, solubility, and safety—using advanced multi-objective algorithms that traditional methods cannot achieve.
Leverage comprehensive databases of antibody sequences, clinical outcomes, and experimental data to continuously refine predictions and improve success rates with each iteration.